Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Colon Cancer treatment details. Biologic therapy. Chemotherapy. Centre René Gauducheau, Nantes, France



Survival: 15.5 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs: Leucovorin
Country: France
   
City/State/Province: Nantes
   
Hospital: Centre René Gauducheau
   
Journal: Link
   
Date: 4/2014

Description:
Patients:
This phase 3 study involved metastatic colorectal cancer patients who were separated into four different groups based on treatment and their genetic status of the KRAS gene. Group A consisted of 325 patients with the wild-type KRAS gene, a median age of 62 years, and 67% male. Group B had 331 patients with a wild-type KRAS gene, a median age of 61 years, and 62% male. Group C consisted of 221 patients with a mutant KRAS gene, a median age of 63 years, and 66% male. Group D had 219 patients with a mutant KRAS gene, a median age of 61 years, and 58% male.

Treatment:
Patients in group A received biologic therapy with panitumumab (an anti-EGFR antibody), and chemotherapy with FOLFOX4 (fluorouracil, oxaliplatin, and leucovorin).

Patients in group B received chemotherapy with FOLFOX4 (fluorouracil, oxaliplatin, and leucovorin).

Patients in group C received biologic therapy with panitumumab (an anti-EGFR antibody) and chemotherapy with FOLFOX4 (fluorouracil, oxaliplatin, and leucovorin).

Patients in group D received chemotherapy with FOLFOX4 (fluorouracil, oxaliplatin, and leucovorin).

Toxicities:
The most severe toxicities in group A were of grade 4 and included grade 3-4 neutropenia, skin toxicity, diarrhea, and nerve toxicity.

The most severe toxicities in group B were of grade 4 and included grade 3-4 neutropenia, diarrhea, and nerve toxicity.

The most severe toxicities in group C were of grade 4 and included grade 3-4 neutropenia, skin toxicity, diarrhea, and nerve toxicity.

The most severe toxicities in group D were of grade 4 and included grade 3-4 neutropenia, diarrhea, and nerve toxicity.

Results:
The median overall survival rates for groups A, B, C, and D were 23.9, 19.7, 15.5, and 19.2 months, respectively.

Support:
This study was supported by Amgen, Inc. (makers of panitumumab – brand name Vectibix)

Correspondence: Dr. Jean-Yves Douillard; email: jean-yves.douillard@ico.unicancer.fr

E-mail to a Friend Email Physician More Information